McKinsey Guided Companies at the Center of the Opioid Crisis
In 2017, less than two years later, the F.D.A. took the rare step of demanding that Endo pull Opana from the market, citing the grave public health consequences of its abuse. The company complied. Over the five years from the appearance of the blood-disease cluster in Tennessee to the drug’s withdrawal from the market, the…